Trials / Recruiting
RecruitingNCT06388122
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biospecimen Collection | Undergo blood sample collection |
Timeline
- Start date
- 2024-04-30
- Primary completion
- 2031-06-15
- Completion
- 2031-06-15
- First posted
- 2024-04-29
- Last updated
- 2026-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06388122. Inclusion in this directory is not an endorsement.